✨ Your Portfolio is fetched and updated from zerodha.
Nano Asset Management

Amerise Biosciences Ltd.

AMERISE

Market Cap
₹5 Cr.
P/E
325.94

Amerise Biosciences Ltd.

  • Amerise Biosciences
  • Global Securities
  • Superior Finlease

FAQs on Amerise Biosciences Ltd. Shareprice

Amerise Biosciences has given lower returns compared to its competitors.
Amerise Biosciences has grown at ~-1.66% over the last 9yrs while peers have grown at a median rate of 5.85%

Amerise Biosciences is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Amerise Biosciences is 325, while 3 year average PE is 25.01.
Also latest EV/EBITDA of Amerise Biosciences is 0.0 while 3yr average is 53.03.

View FAQ's On Business

Growth Table

  • Amerise Biosciences Ltd.
  • Global Securities
  • Superior Finlease

Balance Sheet

  • Amerise Biosciences Ltd.
  • Global Securities
  • Superior Finlease

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Amerise Biosciences Ltd.
  • Global Securities
  • Superior Finlease

Cash Flow

  • Amerise Biosciences Ltd.
  • Global Securities
  • Superior Finlease

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Amerise Biosciences Ltd.
  • Global Securities
  • Superior Finlease

Quarterly Results

  • Amerise Biosciences Ltd.
  • Global Securities
  • Superior Finlease

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Amerise Biosciences Ltd. Financials

Amerise Biosciences balance sheet is weak and might have solvency issues

The net debt of Amerise Biosciences is decreasing.
Latest net debt of Amerise Biosciences is -₹0.59 Crs as of Mar-26.
This is less than Mar-25 when it was -₹0.03 Crs.

The profit is oscillating.
The profit of Amerise Biosciences is ₹0.01 Crs for Mar 2025, -₹0.15 Crs for Mar 2024 and -₹0.12 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Amerise Biosciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech